Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2012.05.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The climb toward intracranial efficacy: Zorifertinib in EGFR-mutant NSCLC with CNS metastases in the EVEREST trial.
Med
January 2025
Division of Neuro-Oncology, Stanford University, Stanford, CA 94305, USA; Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA. Electronic address:
The phase III EVEREST trial evaluating zorifertinib in the treatment of metastatic EGFR-mutant NSCLC was groundbreaking in its specific inclusion of patients with brain metastases. Zorifertinib prolonged systemic and intracranial progression-free survival compared with first-generation EGFR inhibitors, yet questions remain about its efficacy and toxicity compared with osimertinib.
View Article and Find Full Text PDFDisease stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide and radiation-treated glioblastoma.
Neuro Oncol
January 2025
Department of Pathology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Article Synopsis
- The mitochondrial pyruvate carrier (MPC) plays a key role in connecting glycolysis to mitochondrial metabolism and its function in glioblastoma (GBM) post-treatment is not well understood.
- Through in vitro and in vivo studies, the research shows that the MPC is crucial in regulating metabolism after treatments like temozolomide (TMZ) and radiation, specifically inhibiting differentiation in GBM cells.
- The study highlights the potential for using MPC inhibitors to enhance the effectiveness of current therapies and improve survival rates for GBM patients.
A Digital Phenotypic Assessment in Neuro-Oncology (DANO): A Pilot Study on Sociability Changes in Patients Undergoing Treatment for Brain Malignancies.
Cancers (Basel)
January 2025
Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA 02115, USA.
Background: The digital phenotyping tool has great potential for the deep characterization of neurological and quality-of-life assessments in brain tumor patients. Phone communication activities (details on call and text use) can provide insight into the patients' sociability.
Methods: We prospectively collected digital-phenotyping data from six brain tumor patients.
Effect of SNORD113-3/ADAR2 on glycolipid metabolism in glioblastoma via A-to-I editing of PHKA2.
Cell Mol Biol Lett
January 2025
Key Laboratory of Neuro-Oncology in Liaoning Province, Shenyang, 110004, China.
Background: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor, characterized by its poor prognosis. Glycolipid metabolism is strongly associated with GBM development and malignant behavior. However, the precise functions of snoRNAs and ADARs in glycolipid metabolism within GBM cells remain elusive.
View Article and Find Full Text PDFShort- and Long-Term Efficacy of Hyperbaric Oxygen Therapy in Irradiated Breast Cancer Patients With Long-Standing Lymphedema: A Prospective Case Series.
Cancer Rep (Hoboken)
January 2025
Neuro-Mobility Unit, Department of Rehabilitation Medicine, Chiang Mai University, Chiang Mai, Thailand.
Background: Several studies have explored the advantage of treatment with hyperbaric oxygen (HBO) for upper extremity lymphedema in irradiated breast cancer patients and reported controversial results. This prospective case series aimed to document the short- and long-term efficacy of this therapy, focusing on the arm volume and functional assessment in breast cancer patients with a history of long-standing lymphedema for more than 2 years.
Case: Six breast cancer patients with long-standing lymphedema were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!